ArticleGenetics research international2011
Cytogenetics and molecular genetics of myxoid soft-tissue sarcomas.
Article in Genetics research international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Dermatofibrosarcoma Protuberans (DFSP): Current Treatments and Clinical Trials.Current treatment options in oncology · 2025Review
- Management of Regorafenib-Induced Hand-Foot Skin Reaction with Topical Chinese Medicine and Urea Ointment: A Case Report and Literature Review.OncoTargets and therapy · 2025Article
- Genetic Screen in a Preclinical Model of Sarcoma Development Defines Drivers and Therapeutic Vulnerabilities.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.Journal of molecular histology · 2024Review
- Recent Advances in the Diagnosis, Pathogenesis, and Management of Myxoinflammatory Fibroblastic Sarcoma.International journal of molecular sciences · 2024Review
- The Biological Assessment of Shikonin and β,β-dimethylacrylshikonin Using a Cellular Myxofibrosarcoma Tumor Heterogeneity Model.International journal of molecular sciences · 2023Article
- Biology and Management of High-Grade Myxofibrosarcoma: State of the Art and Future Perspectives.Diagnostics (Basel, Switzerland) · 2023Review
- Comparison of the Basal Cell Carcinoma (BCC) Tumour Microenvironment to Other Solid Malignancies.Cancers · 2023Article
- Pediatric dermatofibrosarcoma protuberans: A clinicopathologic and genetic analysis of 66 cases in the largest institution in Southwest China.Frontiers in oncology · 2023Article
- GLUT-1 expression is helpful to distinguish myxofibrosarcoma from nodular fasciitis.Histology and histopathology · 2023Article
- Angiofibroma of soft tissue: Current status of pathology and genetics.Histology and histopathology · 2022Review
- Myoepithelioma-like tumor of the vulvar region: a case report in China and review of the literature.Diagnostic pathology · 2020Review
- Primary cardiac myxofibrosarcoma: case report, literature review and pooled analysis.BMC cancer · 2018Review
- Recurrent myxoinflammatory fibroblastic sarcoma: a case report.Clinical case reports · 2017Article
- Recent translational research into targeted therapy for liposarcoma.Stem cell investigation · 2017Review
- Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.OncoTargets and therapy · 2016Review
- [Molecular pathology of soft tissue tumors: Contribution to diagnosis and therapy prediction].Der Pathologe · 2015Review
- Advances in the targeted therapy of liposarcoma.OncoTargets and therapy · 2015Review
- Head and neck myxofibrosarcoma: a case report and review of the literature.Journal of medical case reports · 2014Review
- Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas.Genes, chromosomes & cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxoid soft-tissue sarcomas represent a heterogeneous group of mesenchymal tumors characterized by a predominantly myxoid matrix, including myxoid liposarcoma (MLS), low-grade fibromyxoid sarcoma (LGFMS), extraskeletal myxoid chondrosarcoma (EMC), myxofibrosarcoma, myxoinflammatory fibroblastic sarcoma (MIFS), and myxoid dermatofibrosarcoma protuberans (DFSP). Cytogenetic and molecular genetic analyses have shown that many of these sarcomas are characterized by recurrent chromosomal translocations resulting in highly specific fusion genes (e.g., FUS-DDIT3 in MLS, FUS-CREB3L2 in LGFMS, EWSR1-NR4A3 in EMC, and COL1A1-PDGFB in myxoid DFSP). Moreover, recent molecular analysis has demonstrated a translocation t(1; 10)(p22; q24) resulting in transcriptional upregulation of FGF8 and NPM3 in MIFS. Most recently, the presence of TGFBR3 and MGEA5 rearrangements has been identified in a subset of MIFS. These genetic alterations can be utilized as an adjunct in diagnostically challenging cases. In contrast, most myxofibrosarcomas have complex karyotypes lacking specific genetic alterations. This paper focuses on the cytogenetic and molecular genetic findings of myxoid soft-tissue sarcomas as well as their clinicopathological characteristics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.